Prevalence and Risk Factors of Pediatric Type 1 Diabetes (T1D)

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Investigators sought to test the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention on levels of HbA1c.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Diamyd to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2 was granted Fast Track designation by the FDA in February 2024.

"Taken together, our findings suggest the relative protection associated with having a mother versus father with type 1 diabetes is a long-term effect that extends into adult life," stated study investigators.